Tag: Adc

Over the past two decades, the development of sophisticated targeted therapies like antibody-drug conjugates (ADCs) has revolutionized cancer treatment, highlighting the importance of understanding **what is a conjugate in medical terms**. A conjugate is a compound formed by chemically joining two or more different substances, with this strategic chemical union playing diverse and crucial roles in pharmacology and medicine.

Over two decades, antibody-drug conjugates (ADCs) have transformed targeted cancer therapy, and the next-generation platform using a **DXd drug** as a payload is at the forefront of this innovation. This technology, pioneered by Daiichi Sankyo, is built around a potent topoisomerase I inhibitor, designed to precisely deliver chemotherapy to cancer cells while minimizing systemic harm.

According to the FDA, Tivdak was granted accelerated approval in 2021 for the treatment of recurrent or metastatic cervical cancer in adults who have progressed during or after previous chemotherapy. This targeted therapy, known by its generic name tisotumab vedotin-tftv, is a specialized antibody-drug conjugate (ADC) that functions differently from traditional chemotherapy by directly targeting cancer cells.